Identifying markers for chemotherapy response in gastric and cardia adenocarcinomas
Biomoleculars Markers of Sensitivity to Pre- and Post-operative Chemotherapy of Gastric and Cardia Adenocarcinomas: a Pilot Study
This study is testing if certain biological markers in patients with stomach cancer can help doctors predict how well they will respond to chemotherapy before and after surgery.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Strasbourg) |
| Trial ID | NCT02491840 on ClinicalTrials.gov |
What this trial studies
This pilot study aims to identify biomolecular markers that indicate sensitivity to pre- and post-operative chemotherapy in patients with gastric and cardia adenocarcinomas. By analyzing biopsies taken at diagnosis, the study will categorize patients into 'good' and 'bad' responders to chemotherapy protocols such as EOX and FOLFOX. Additionally, the study will assess the impact of patients' lifestyle on chemotherapy response and investigate markers related to cancer stem cells. The goal is to improve treatment strategies and outcomes for these patients.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old diagnosed with gastric or cardia adenocarcinoma who can provide informed consent.
Not a fit: Patients with other cancers undergoing chemotherapy or those who are pregnant or breastfeeding may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective chemotherapy treatments for patients with gastric and cardia adenocarcinomas.
How similar studies have performed: While this study explores a specific approach to identifying chemotherapy sensitivity, similar studies have shown promise in using biomolecular markers for treatment personalization in cancer care.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Gastric adenocarcinoma (any location) or cardia adenocarcinoma * Age\> 18 years * WHO Index≤ 3 * Subject having signed an informed consent Exclusion Criteria: * Other cancers undergoing chemotherapy treatment * Pregnant or breastfeeding * Inability to understand information (understanding with difficulties ...)
Where this trial is running
Strasbourg
- University Hospital, Strasbourg, france — Strasbourg, France (Recruiting)
Study contacts
- Principal investigator: Benoît ROMAIN, MD — University Hospital, Strasbourg, France
- Study coordinator: Benoît ROMAIN, MD
- Email: benoit.romain@chru-strasbourg.fr
- Phone: 03/88/12/72/43
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.